Citations

Clear

477 citation(s) found for "Wallace, AM".

Abstract MP020: Long-term, Visit-to-visit Blood Pressure Variability and the Risk of Total Mortality, MI, and Stroke in the Cardiovascular Health Study
Suchy‐Dicey, Astrid M. , Wallace, Erin R. , Elkind, Mitchell S, Aguilar, Maria I. , Gottesman, Rebecca, Voorman, Arend, Longstreth, W.T. , Rice, Kenneth , Kronmal, Richard A. , Psaty, Bruce M.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 125 | Issue: suppl_10 | Pages: No page available

10.1161/circ.125.suppl_10.amp020 Get It

Introduction: Recent reports have linked visit-to-visit blood pressure (BP) variability to risk of mortality and stroke, independent of the effect of mean BP level. We sought to confirm these findings in the Cardiovascular Health Study (CHS), a cohort study of cardiovascular risk factors. Hypothesis: Variability in visit-to-visit SBP, defined as intraindividual SBP SD, is directly associated with risk of mortality, myocardial infarction (MI), and stroke, independent of intraindividual SBP mean and trend over time. Methods: Participants from CHS were eligible if they attended their first five annual clinic visits and did not have stroke, MI, or death by the 5th visit (N=3513). Follow-up started at the 5th visit and extended through June 2008. Analyses were further restricted to subjects who used no antihypertensive medications during the entire 5-year baseline period (non-users, n=1570) and subjects who used the same antihypertensive regimen during that time (users, n=978). Intraindividual SBP variables were defined using each subject’s 5-visit BPs. Cox proportional hazards models estimated adjusted hazard ratios (HR) per standard deviation (SD) increase in intraindividual SD (iSD) SBP or intraindividual mean (iMean) SBP. Results were stratified on medication use or non-use. Results: Participants’ mean age was 71 years, 42% were men, and 95% were white. Mean(SD) of iSD SBP was 9.8(4.6) mmHg for anti-hypertensive medications non-users and 12.0(6.0) mmHg for users. iMean SBP was significantly associated with all 3 outcomes among non-users and with stroke among users (table). iSD SBP was significantly associated with mortality in all participants and with MI among non-users; associations for stroke were not significant. Conclusion: Long-term visit-to-visit SBP variability may be an important determinant of MI and mortality risk in the elderly. Results for stroke are not consistent with other, previous reports. More research is needed to determine the clinical implications.
Artificial intelligence and colonoscopy experience: lessons from two randomised trials
Repici, Alessandro , Spadaccini, Marco , Antonelli, Giulio , Correale, Loredana , Maselli, Roberta , Galtieri, P.A. , Pellegatta, Gaia , Capogreco, Antonio , Milluzzo, Sebastian Manuel , Lollo, Gianluca, Paolo, Dhanai Di , Badalamenti, Matteo , Ferrara, E.C. , Fugazza, Alessandro , Carrara, Silvia , Amato, Arnaldo , Gottardi, Andrea De , Spada, Cristiano , Wallace, Michael B. , Hassan, Cesare , Rondonotti, Emanuele , Amato, Arnaldo , Radaelli, Franco , Rösch, Thomas , Hassan, Cesare , Spadaccini, Marco , Wallace, Michael B , Fugazza, Alessandro , Anderloni, Andrea , Rondonotti, Emanuele , Radaelli, Franco , Savevski, Victor , Sharma, Prateek

Mayo Clinic

Gut | June 29, 2021 | Volume: 71 | Issue: 4 | Pages: 757-765

10.1136/gutjnl-2021-324471 | PMID 34187845 Get It

Background and aims Artificial intelligence has been shown to increase adenoma detection rate (ADR) as the main surrogate outcome parameter of colonoscopy quality. To which extent this effect may be related to physician experience is not known. We performed a randomised trial with colonoscopists in their qualification period (AID-2) and compared these data with a previously published randomised trial in expert endoscopists (AID-1). Methods In this prospective, randomised controlled non-inferiority trial (AID-2), 10 non-expert endoscopists (<2000 colonoscopies) performed screening/surveillance/diagnostic colonoscopies in consecutive 40–80 year-old subjects using high-definition colonoscopy with or without a real-time deep-learning computer-aided detection (CADe) (GI Genius, Medtronic). The primary outcome was ADR in both groups with histology of resected lesions as reference. In a post-hoc analysis, data from this randomised controlled trial (RCT) were compared with data from the previous AID-1 RCT involving six experienced endoscopists in an otherwise similar setting. Results In 660 patients (62.3±10 years; men/women: 330/330) with equal distribution of study parameters, overall ADR was higher in the CADe than in the control group (53.3% vs 44.5%; relative risk (RR): 1.22; 95% CI: 1.04 to 1.40; p<0.01 for non-inferiority and p=0.02 for superiority). Similar increases were seen in adenoma numbers per colonoscopy and in small and distal lesions. No differences were observed with regards to detection of non-neoplastic lesions. When pooling these data with those from the AID-1 study, use of CADe (RR 1.29; 95% CI: 1.16 to 1.42) and colonoscopy indication, but not the level of examiner experience (RR 1.02; 95% CI: 0.89 to 1.16) were associated with ADR differences in a multivariate analysis. Conclusions In less experienced examiners, CADe assistance during colonoscopy increased ADR and a number of related polyp parameters as compared with the control group. Experience appears to play a minor role as determining factor for ADR. Trial registration number NCT:04260321.
Calcium supplements and the risk of myocardial infarction
Heaney, Robert P., Kopecky, Stephen L. , Hathcock, John N., Mackay, Douglas M., Wallace, Taylor C. , Maki, Kevin Carl , MacKay, Douglas

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 26 | Issue: S1 | Pages: No page available

10.1096/fasebj.26.1_supplement.1008.2 Get It

This poster presents an expert consensus position on the current controversy regarding calcium supplement use and risk of myocardial infarction. In November 2011, The CRN Foundation with the support of the National Osteoporosis Foundation and National Bone Health Alliance convened an expert panel of scientists from the nutrition and medical communities to review the total body of evidence and specifically studies relating calcium supplements to an increased risk of myocardial infarction. Because of the many data limitations present in the supporting studies relating calcium supplements to an increased risk of myocardial infarction and contrast to the large majority of the literature accompanied with recent reanalyses of the data, no change in prescribing practice is currently recommended. Prescribers should consider the potential benefits of calcium supplements for prevention of osteoporotic fractures based on an individual's personal dietary intake. Positive outcomes of calcium supplementation such as prevention of obesity and colorectal cancers may also carry weight in support of calcium supplements when individual dietary intakes are inadequate to meet IOM recommendations.
Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA
Eckmann, Jason D. , Burger, Kelli N. , Bering, Jamie , Rodríguez, Eduardo A. , Prichard, David O. , Wallace, Michael B. , Kane, Sunanda V. , Gurudu, Suryakanth, Mahoney, Douglas W. , Kahn, Allon , Gurudu, Suryakanth R, Kisiel, John B , Wallace, Michael B , Ebner, Derek W. , Rutten, Lila J. Finney , Kisiel, John B.

Mayo Clinic

Clinical and Translational Gastroenterology | June 18, 2021 | Volume: 12 | Issue: 6 | Pages: e00375

10.14309/ctg.0000000000000375 | PMID 34140458 Get It

INTRODUCTION: Significant variability between colonoscopy operators contributes to postcolonoscopy colorectal cancers (CRCs). We aimed to estimate postcolonoscopy colorectal neoplasia (CRN) detection by multi-target stool DNA (mt-sDNA), which has not previously been studied for this purpose. METHODS: In a retrospective cohort of patients with +mt-sDNA and completed follow-up colonoscopy, positive predictive value (PPV) for endpoints of any CRN, advanced adenoma, right-sided neoplasia, sessile serrated polyps (SSP), and CRC were stratified by the time since previous colonoscopy (0–9, 10, and ≥11 years). mt-sDNA PPV at ≤9 years from previous average-risk screening colonoscopy was used to estimate CRN missed at previous screening colonoscopy. RESULTS: Among the 850 studied patients with +mt-sDNA after a previous negative screening colonoscopy, any CRN was found in 535 (PPV 63%). Among 107 average-risk patients having +mt-sDNA ≤9 years after last negative colonoscopy, any CRN was found in 67 (PPV 63%), advanced neoplasia in 16 (PPV 15%), right-sided CRN in 48 (PPV 46%), and SSP in 20 (PPV 19%). These rates were similar to those in 47 additional average risk persons with previous incomplete colonoscopy and in an additional 68 persons at increased CRC risk. One CRC (stage I) was found in an average risk patient who was mt-sDNA positive 6 years after negative screening colonoscopy. DISCUSSION: The high PPV of mt-sDNA 0–9 years after a negative screening colonoscopy suggests that lesions were likely missed on previous examination or may have arisen de novo . mt-sDNA as an interval test after negative screening colonoscopy warrants further study.
Survey Finds Gender Disparities Impact Both Women Mentors and Mentees in Gastroenterology
Rabinowitz, Loren , Zylberberg, Haley M. , Dixon, Rebekah E. , David, Yakira , Aroniadis, Olga C. , Chiang, Austin L. , Christie, Jennifer, Fayad, Nabil , Ha, Christina , Harris, Lucinda A. , Ko, Cynthia W. , Kwah, Joann , Raffals, Laura E. , Rex, Douglas K. , Siddiqui, Uzma D. , Smith, Michael S. , Wallace, Michael B. , Woods, Karen, Crowe, Sheila E., Kumta, Nikhil A. , Kim, Michelle Kang , Greenwald, David A. , Fichera, Alessandro , Wallace, Michael B , Grinspan, Lauren Tal , Kolb, Jennifer M. , Lee, Linda , Lieberman, David A. , Shah, Shailja C. , Williams, Reneé

Mayo Clinic

American Journal of Gastroenterology | June 18, 2021 | Volume: 116 | Issue: 9 | Pages: 1876-1884

10.14309/ajg.0000000000001341 | PMID 34140455 Get It

INTRODUCTION: Gastroenterologists at all levels of practice benefit from formal mentoring. Much of the current literature on mentoring in gastroenterology is based on expert opinion rather than data. In this study, we aimed to identify gender-related barriers to successful mentoring relationships from the mentor and mentee perspectives. METHODS: A voluntary, web-based survey was distributed to physicians at 20 academic institutions across the United States. Overall, 796 gastroenterology fellows and faculty received the survey link, with 334 physicians responding to the survey (42% response rate), of whom 299 (90%; 129 women and 170 men) completed mentorship questions and were included in analysis. RESULTS: Responses of women and men were compared. Compared with men, more women preferred a mentor of the same gender (38.6% women vs 4.2% men, P < 0.0001) but less often had one (45.5% vs 70.2%, P < 0.0001). Women also reported having more difficulty finding a mentor (44.4% vs 16.0%, P < 0.0001) and more often cited inability to identify a mentor of the same gender as a contributing factor (12.8% vs 0.9%, P = 0.0004). More women mentors felt comfortable advising women mentees about work-life balance (88.3% vs 63.8%, P = 0.0005). Nonetheless, fewer women considered themselves effective mentors (33.3% vs 52.6%, P = 0.03). More women reported feeling pressured to mentor because of their gender (39.5% vs 0.9% of men, P < 0.0001). Despite no gender differences, one-third of respondents reported negative impact of the COVID-19 pandemic on their ability to mentor and be mentored. DISCUSSION: Inequities exist in the experiences of women mentees and mentors in gastroenterology, which may affect career advancement and job satisfaction.
Abstract PR07: Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy
Klichinsky, Michael , Shestova, Olga, Best, Andrew, Blouch, Kristin, Lu, Xueqing Maggie , Wallace, Stephen R., Kozlowski, Miroslaw , Shestov, Maksim, García, Benjamin A. , June, Carl H. , Ruella, Marco , Kenderian, Saad S. , Kim, Miriam Y. , O’Connor, Roddy S. , Marchione, Dylan M. , Gill, Saar

Mayo Clinic

Cancer Immunology Research | June 10, 2021 | Volume: 8 | Issue: 4_Supplement | Pages: PR07-PR07

10.1158/2326-6074.tumimm18-pr07 Get It

Abstract Despite recent landmark advances in T-cell immunotherapy for the treatment of human cancer, metastatic solid tumors remain an intractable challenge. Macrophages are often the most abundant immune cell in the tumor microenvironment (TME), where they may convert into immunosuppressive (M2) tumor-associated macrophages (TAMs) and participate in disease progression. Currently, macrophage-orientated immunotherapeutic approaches under clinical development in oncology seek to reduce TAM infiltration (CSF-1 antagonists) or enhance TAM phagocytosis (CD47 antagonists). Transfer of autologous, activated, but nontargeted macrophages failed to demonstrate antitumor efficacy in past clinical trials. We hypothesized that genetically engineering human macrophages with CARs against tumor-associated antigens could redirect their phagocytic activity and lead to therapeutic efficacy with the potential for the induction of an antitumor T-cell response. We first demonstrate that CD3-zeta-based CARs are capable of inducing phagocytosis in human THP-1 macrophages, while truncated intracellular-domain deficient CARs were not. Targeted phagocytosis and clearance of CD19+, mesothelin +, and HER2+ cells by CARs targeted against each respective antigen was significantly superior to that by control untransduced (UTD) macrophages. We demonstrate that primary human macrophages, which are resistant to most viral vectors, are efficiently transduced by the chimeric fiber adenoviral vector Ad5f35 (~70% in 10 normal donors). Using Ad5f35, we engineered primary human macrophages with a CD3-zeta-based CAR against HER2. Anti-HER2 primary human CAR macrophages demonstrated targeted phagocytosis against HER2+ but not HER2- cell lines, with phagocytic activity dependent on both the CAR and antigen densities. Furthermore, CAR, but not UTD, macrophages led to potent dose-dependent killing of three distinct HER2-high cell lines in vitro. We sought to test the efficacy of anti-HER2 primary human macrophages in xenograft models of human HER2+ ovarian cancer. A single dose of CAR, but not UTD macrophages, led to tumor regression and improved overall survival in both intraperitoneal and disseminated models of disease. We show that macrophage transduction with Ad5f35, a double-stranded DNA virus, leads to a broad gene expression change, an interferon signaling signature, and phenotypic clustering toward classically activated M1 macrophages. CAR macrophages upregulated co-stimulatory ligand and antigen processing/presentation genes and led to enhanced T-cell stimulation in vitro and in vivo. Lastly, CAR, but not UTD, macrophages showed a broad resistance for M2 conversion in response to immunosuppressive cytokines. In conclusion, we show that primary human CAR macrophages are capable of targeted tumor phagocytosis, lead to improved overall survival in xenograft models, and demonstrate enhanced T-cell stimulation. CAR macrophages are a novel cell therapy platform for the treatment of human cancer. This abstract is also being presented as Poster B29. Citation Format: Michael Klichinsky, Marco Ruella, Olga Shestova, Andrew Best, Kristin Blouch, Xueqing M. Lu, Saad S. Kenderian, Miriam Y. Kim, Roddy O'Connor, Stephen Wallace, Miroslaw Kozlowski, Dylan M. Marchione, Maksim Shestov, Benjamin A. Garcia, Carl June, Saar Gill. Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr PR07.
What gastroenterologists should know about SARS–CoV 2 vaccine: World Endoscopy Organization perspective
Spadaccini, Marco , Canziani, Lorenzo Maria , Aghemo, Alessio , Lleò, Ana , Maselli, Roberta , Carrara, Silvia , Fugazza, Alessandro , Pellegatta, Gaia , Galtieri, P.A. , Hassan, Cesare , Greenwald, David A. , Pochapin, Mark , Wallace, Michael B. , Röesch, Thomas, Raju, Gottumukkala S. , Repici, Alessandro , Canziani, Lorenzo , Fugazza, Alessandro , Spadaccini, Marco , Hassan, Cesare , Wallace, Michael B , Anderloni, Andrea , Sharma, Prateek , Bhandari, Pradeep , Emura, Fabian

Mayo Clinic

United European Gastroenterology Journal | June 9, 2021 | Volume: 9 | Issue: 7 | Pages: 787-796

10.1002/ueg2.12103 | PMID 34102015 Get It

AbstractBackgroundThe novel Coronavirus (SARS‐CoV‐2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID‐19 vaccines, and a few more are going to be approved soon.MethodsSeveral different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non‐replicating viral vector vaccines, RNA based vaccines, DNA based vaccines).ResultsSince vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS‐CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients.ConclusionsThus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID‐19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination.
Anxiety, Depression, and Quality of Life After Procedural Intervention for Uterine Fibroids
Nicholson, Wanda K. , Parry, John Preston , Zhang, Shuaiqi , Laughlin‐Tommaso, Shannon K. , Jacoby, Vanessa L. , Anchan, Raymond M. , Venable, Sateria, Shiflett, Amber, Wegienka, Ganesa , Maxwell, G. Larry , Wojdyla, Daniel , Marsh, Erica E. , Laughlin-Tommaso, Shannon , Diamond, M P , Wallace, Kedra , Stewart, Elizabeth A. , Wise, Lauren Anne , Myers, Evan R.

Mayo Clinic

Journal of Women's Health | June 8, 2021 | Volume: 31 | Issue: 3 | Pages: 415-424

10.1089/jwh.2020.8915 | PMID 34101502 Get It

Background: Quality of life (QOL) and psychological health has been reported to be decreased among women with gynecological conditions such as uterine fibroids (UFs). Materials and Methods: Women enrolled in the Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry, receiving procedural therapy for symptomatic UFs, were eligible for this analysis if they completed a series of health-related QOL surveys administered at three time points (baseline, 6–12 weeks postprocedure, and 1 year postprocedure; n = 1486). Ethical approval for this study was obtained at each recruiting site and the coordinating center (NCT02260752, clinicaltrials.gov ). Results: More than 26% ( n = 393) of women reported moderate anxiety/depression on the baseline anxiety/depression domain of the Euro-QOL 5-dimension instrument. At both the 6–12 weeks and 1-year postprocedural follow-up, there was significant improvement in the UF QOL symptom severity score ( p < 0.001, p < 0.001), the total UF symptom QOL score ( p < 0.001, p < 0.001), and the Euro-QOL 5-dimension visual analog scale ( p < 0.001, p = 0.004) compared with the preprocedural baseline scores. The reporting of anxiety/depression decreased by 66.4% among women who were at baseline, whereas 5.6% of women previously reporting no anxiety/depression reported anxiety/depression at the 1-year follow-up. Conclusion: UF symptoms were more severe among women reporting anxiety/depression at baseline. At the 1-year follow-up, health-related QOL scores improved among all women and the prevalence of anxiety/depression decreased in most, but not all women, whereas severity of anxiety/depression worsened in a small percentage of women (5.6%). Overall, these results suggest that UF treatment improves symptoms of anxiety/depression associated with symptomatic UFs.
A Novel Nodule Edge Sharpness Radiomic Biomarker Improves Performance of Lung-RADS for Distinguishing Adenocarcinomas from Granulomas on Non-Contrast CT Scans
Alilou, Mehdi , Prasanna, Prateek , Gupta, Amit , Rajiah, Prabhakar , Jacono, Frank J., Velcheti, Vamsidhar , Gilkeson, Robert , Linden, Philip A. , Madabhushi, Anant , Madabhushi, Anant , Rajiah, Prabhakar , Bera, Kaustav , Yang, Michael

Mayo Clinic

Cancers | June 3, 2021 | Volume: 13 | Issue: 11 | Pages: 2781

10.3390/cancers13112781 | PMID 34205005 Get It

The aim of this study is to evaluate whether NIS radiomics can distinguish lung adenocarcinomas from granulomas on non-contrast CT scans, and also to improve the performance of Lung-RADS by reclassifying benign nodules that were initially assessed as suspicious. The screening or standard diagnostic non-contrast CT scans of 362 patients was divided into training (St, N = 145), validation (Sv, N = 145), and independent validation (Siv, N = 62) sets from different institutions. Nodules were identified and manually segmented on CT images by a radiologist. A series of 264 features relating to the edge sharpness transition from the inside to the outside of the nodule were extracted. The top 10 features were used to train a linear discriminant analysis (LDA) machine learning classifier on St. In conjunction with the LDA classifier, NIS radiomics classified nodules with an AUC of 0.82 ± 0.04, 0.77, and 0.71 respectively on St, Sv, and Siv. We evaluated the ability of the NIS classifier to determine the proportion of the patients in Sv that were identified initially as suspicious by Lung-RADS but were reclassified as benign by applying the NIS scores. The NIS classifier was able to correctly reclassify 46% of those lesions that were actually benign but deemed suspicious by Lung-RADS alone on Sv.
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.
Krishnan, Amrita , Arendt, Bonnie K., Dasari, Surendra , Efebera, Yvonne A. , Geller, Nancy L. , Hahn, Theresa , Kohlhagen, Mindy , Landau, Heather , Pasquini, Marcelo C. , Qazilbash, Muzaffar H. , Shah, Nina , Vesole, David H. , Wallace, Paul K. , Stadtmauer, Edward A. , Murray, David , Dispenzieri, Angela , Giralt, Sergio , Hari, Parameswaran , McCarthy, Philip L. , Vogl, Dan T.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 8009-8009

10.1200/jco.2021.39.15_suppl.8009 Get It

8009 Background: Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses have been associated with better progression free survival (PFS) and overall survival (OS). Serum (SIFE) and urine immunofixation are the currently used markers for biochemical documentation of CR after which marrow is tested for plasma cell clearance. Next generation flow cytometry and sequencing are used to document the presence of minimal residual disease (MRD). Mass spectrometry of blood by MALDI (Mass-Fix) is a new simple, inexpensive, sensitive, and specific means of detecting monoclonal immunoglobulins. To better test the hypothesis that Mass-Fix is superior to existing methodologies to predict for survival outcomes—especially SIFE-- samples from the STAMINA trial (NCT01109004), a trial comparing 3 transplant approaches among patients who have already received induction, were employed. Methods: Five-hundred and seventy-five patients were included. Samples from enrollment post-induction (post-I) and 1-year post enrollment (1YR) were tested when available. Four response parameters were assessed univariately: Mass-Fix, SIFE, complete response, and MRD by next generation flow cytometry. Mass spectrometry spectra were evaluated in a blinded fashion. Complete response was according to the 2006 International Myeloma Working Group criteria. Multivariate Cox proportional hazard models using stepwise regression were developed to explore the independent effect of the different response parameters on PFS and OS and interactions with other risk factors. Results: Of the 4 response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses (Table). Of the 4 post-I measurements, only MRD predicted for PFS; however, Mass-Fix was the only post-I measurement to predict for OS. Of all the 1-year measures, both 1YR Mass-Fix and 1YR MRD positivity predicted for inferior PFS and OS. In models including MRD and Mass-Fix, SIFE and CR were not prognostic for PFS or OS. Conclusions: Mass-Fix is a powerful means to track monoclonal proteins. The full utility of Mass-Fix was not exploited given the absence of a diagnostic sample and the fact that only serum (and not urine) was tested. Despite these limitations, it performed well at pre-induction and at 1 year. Mass-Fix provides a convenient and non-invasive means of predicting for myeloma outcomes. Clinical trial information: NCT01109004. [Table: see text]